Integrated Filing — IndAS



General information about company

Scrip Code 532321
NSE Symbol ZYDUSLIFE
MSEI Symbol NOTLISTED
ISIN INE010B01027
Name of company ZYDUS LIFESCIENCES LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2025
Date of end of financial year 31-03-2026
Date of board meeting when results were approved 19-05-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 08-05-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Fourth quarter
Nature of report standalone or consolidated Consolidated
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Audited
Segment Reporting Multi segment
Description of single segment
Start date and time of board meeting 19-05-2026   12:00:00
End date and time of board meeting 19-05-2026   14:00:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-01-2026 01-04-2025
B Date of end of reporting period 31-03-2026 31-03-2026
C Whether results are audited or unaudited Unaudited Audited
D Nature of report standalone or consolidated Consolidated Consolidated
1 Income
Revenue from operations 7,58,700.00 27,14,840.00
Other income 13,420.00 50,950.00
Total income 7,72,120.00 27,65,790.00
2 Expenses
(a) Cost of materials consumed 1,34,720.00 5,10,960.00
(b) Purchases of stock-in-trade 97,170.00 3,07,050.00
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade (34,260.00) (88,750.00)
(d) Employee benefit expense 1,23,880.00 4,41,790.00
(e) Finance costs 12,300.00 43,890.00
(f) Depreciation, depletion and amortisation expense 50,840.00 1,40,800.00
(f) Other Expenses
1 Other expenses 2,46,240.00 8,24,330.00
2 Net (gain)/ loss on foreign currency transactions (64,490.00) (1,28,050.00)
Total other expenses 1,81,750.00 6,96,280.00
Total expenses 5,66,400.00 20,52,020.00
3 Total profit before exceptional items and tax 2,05,720.00 7,13,770.00
4 Exceptional items (39,750.00) (51,660.00)
5 Total profit before tax 1,65,970.00 6,62,110.00
6 Tax expense
7 Current tax 52,560.00 1,37,950.00
8 Deferred tax (20,720.00) 21,520.00
9 Total tax expenses 31,840.00 1,59,470.00
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 1,34,130.00 5,02,640.00
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method (30.00) 9,710.00
16 Total profit (loss) for period 1,34,100.00 5,12,350.00
17 Other comprehensive income net of taxes (48,340.00) (77,480.00)
18 Total Comprehensive Income for the period 85,760.00 4,34,870.00
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent 1,27,250.00 5,04,000.00
Total profit or loss, attributable to non-controlling interests 6,850.00 8,350.00
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent 79,020.00 4,26,730.00
Total comprehensive income for the period attributable to owners of parent non-controlling interests 6,740.00 8,140.00
21 Details of equity share capital
Paid-up equity share capital 10,060.00 10,060.00
Face value of equity share capital 1 1
27 Details of debt securities
22 Reserves excluding revaluation reserve 27,01,080.00
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 12.65 50.09
Diluted earnings (loss) per share from continuing operations 12.65 50.09
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 12.65 50.09
Diluted earnings (loss) per share from continuing and discontinued operations 12.65 50.09
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2025
Date of end of reporting period 31-03-2026
Whether results are audited or unaudited Audited
Nature of report standalone or consolidated Consolidated
Assets
1 Non-current assets
Property, plant and equipment 9,23,070.00
Capital work-in-progress 1,16,570.00
Investment property 0.00
Goodwill 7,54,270.00
Other intangible assets 7,33,240.00
Intangible assets under development 2,53,280.00
Biological assets other than bearer plants 0.00
Investments accounted for using equity method 1,16,660.00
Non-current financial assets
Non-current investments 59,750.00
Trade receivables, non-current 0.00
Loans, non-current 20.00
Other non-current financial assets
1 Other Financial Assets 3,440.00
Total of other non-current financial assets 3,440.00
Total non-current financial assets 63,210.00
Deferred tax assets (net) 2,10,860.00
Other non-current assets
1 Other non-current assets 68,420.00
2 Assets for Current tax (Net) 10,470.00
Total of other non-current assets 78,890.00
Total non-current assets 32,50,050.00
2 Current assets
Inventories 5,62,810.00
Current financial asset
Current investments 5,77,580.00
Trade receivables, current 5,41,570.00
Cash and cash equivalents 85,520.00
Bank balance other than cash and cash equivalents 56,140.00
Loans, current 370.00
Other current financial assets
Total of other current financial assets 21,690.00
Total current financial assets 12,82,870.00
Current tax assets (net)
Other current assets
1 Other current assets 1,44,930.00
Total of other current assets 1,44,930.00
Total current assets 19,90,610.00
3 Non-current assets classified as held for sale 0.00
4 Regulatory deferral account debit balances and related deferred tax Assets 0.00
Total assets 52,40,660.00
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 10,060.00
Other equity 27,01,080.00
Total equity attributable to owners of parent 27,11,140.00
Non controlling interest 2,47,080.00
Total equity 29,58,220.00
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 3,18,800.00
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0.00
Total Trade payable 0.00
Other non-current financial liabilities
1 Lease liabilities 66,830.00
2 Other financial liabilities 1,07,640.00
Total of other non-current financial liabilities 1,74,470.00
Total non-current financial liabilities 4,93,270.00
Provisions, non-current 44,530.00
Deferred tax liabilities (net) 1,73,400.00
Deferred government grants, Non-current 0.00
Other non-current liabilities
1 Other Non-Current Liabilities 50.00
Total of other non-current liabilities 50.00
Total non-current liabilities 7,11,250.00
Current liabilities
Current financial liabilities
Borrowings, current 8,58,150.00
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 15,400.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 2,69,110.00
Total Trade payable 2,84,510.00
Other current financial liabilities
1 Lease liabilities 5,820.00
2 Other financial liabilities 2,90,460.00
Total of other current financial liabilities 2,96,280.00
Total current financial liabilities 14,38,940.00
Other current liabilities 47,770.00
1 Other current liabilities 47,770.00
Total of other current liabilities 47,770.00
Provisions, current 47,850.00
Current tax liabilities (Net) 36,630.00
Deferred government grants, Current 0.00
Total current liabilities 15,71,190.00
3 Liabilities directly associated with assets in disposal group classified as held for sale
4 Regulatory deferral account credit balances and related deferred tax liability
Total liabilities 22,82,440.00
Total equity and liabilites 52,40,660.00
Disclosure of notes on assets and liabilities



Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-01-2026 01-04-2025
Date of end of reporting period 31-03-2026 31-03-2026
Whether results are audited or unaudited Unaudited Audited
Nature of report standalone or consolidated Consolidated Consolidated
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
1 Pharmaceuticals 5,77,610.00 22,41,210.00
2 Consumer products 1,48,340.00 3,95,400.00
3 Medical technologies 32,750.00 78,230.00
Total Segment Revenue 7,58,700.00 27,14,840.00
Less: Inter segment revenue
Revenue from operations 7,58,700.00 27,14,840.00
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
1 Pharmaceuticals 1,93,960.00 7,04,880.00
2 Consumer products 17,640.00 26,710.00
3 Medical technologies (5,880.00) (17,820.00)
Total Profit before tax 2,05,720.00 7,13,770.00
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax 2,05,720.00 7,13,770.00
3 (Segment Asset - Segment Liabilities)
Segment Asset
1 Pharmaceuticals 35,79,830.00 35,79,830.00
2 Consumer products 10,30,620.00 10,30,620.00
3 Medical technologies 6,30,210.00 6,30,210.00
Total Segment Asset 52,40,660.00 52,40,660.00
Un-allocable Assets 0.00 0.00
Net Segment Asset 52,40,660.00 52,40,660.00
4 Segment Liabilities
Segment Liabilities
1 Pharmaceuticals 11,96,840.00 11,96,840.00
2 Consumer products 4,47,900.00 4,47,900.00
3 Medical technologies 6,37,700.00 6,37,700.00
Total Segment Liabilities 22,82,440.00 22,82,440.00
Un-allocable Liabilities 0.00 0.00
Net Segment Liabilities 22,82,440.00 22,82,440.00
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-01-2026 01-04-2025
B Date of end of reporting period 31-03-2026 31-03-2026
C Whether results are audited or unaudited Unaudited Audited
D Nature of report standalone or consolidated Consolidated Consolidated
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Items that will not be reclassified to profit or loss (6,940.00) (3,290.00)
Total Amount of items that will not be reclassified to profit and loss (6,940.00) (3,290.00)
2 Income tax relating to items that will not be reclassified to profit or loss 1,650.00 1,350.00
3 Amount of items that will be reclassified to profit and loss
1 Items that will be reclassified to profit or loss (39,890.00) (72,980.00)
2 Share of OCI of joint ventures (net of tax) 140.00 140.00
Total Amount of items that will be reclassified to profit and loss (39,750.00) (72,840.00)
4 Income tax relating to items that will be reclassified to profit or loss 0.00 0.00
5 Total Other comprehensive income (48,340.00) (77,480.00)



Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2025
B Date of end of reporting period 31-03-2026
C Whether results are audited or unaudited Audited
D Nature of report standalone or consolidated Consolidated
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 6,62,110.00
Adjustments for reconcile profit (loss)
Adjustments for finance costs 36,500.00
Adjustments for decrease (increase) in inventories (41,240.00)
Adjustments for decrease (increase) in trade receivables, current (85,810.00)
Adjustments for decrease (increase) in trade receivables, non-current 0.00
Adjustments for decrease (increase) in other current assets (46,180.00)
Adjustments for decrease (increase) in other non-current assets 0.00
Adjustments for other financial assets, non-current 0.00
Adjustments for other financial assets, current 0.00
Adjustments for other bank balances 0.00
Adjustments for increase (decrease) in trade payables, current (79,510.00)
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities (9,630.00)
Adjustments for increase (decrease) in other non-current liabilities 0.00
Adjustments for depreciation and amortisation expense 1,40,800.00
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0.00
Adjustments for provisions, current 5,490.00
Adjustments for provisions, non-current (5,400.00)
Adjustments for other financial liabilities, current 0.00
Adjustments for other financial liabilities, non-current 0.00
Adjustments for unrealised foreign exchange losses gains (1,75,330.00)
Adjustments for dividend income 120.00
Adjustments for interest income 42,250.00
Adjustments for share-based payments 0.00
Adjustments for fair value losses (gains) (2,920.00)
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow (230.00)
Other adjustments to reconcile profit (loss) 0.00
Other adjustments for non-cash items 14,480.00
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments for reconcile profit (loss) (2,91,350.00)
Net cash flows from (used in) operations 3,70,760.00
Dividends received 0.00
Interest paid 0.00
Interest received 0.00
Income taxes paid (refund) 1,59,100.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) operating activities 2,11,660.00
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0.00
Cash flows used in obtaining control of subsidiaries or other businesses 5,87,930.00
Other cash receipts from sales of equity or debt instruments of other entities 11,200.00
Other cash payments to acquire equity or debt instruments of other entities 34,520.00
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property, plant and equipment 2,490.00
Purchase of property, plant and equipment 3,39,400.00
Proceeds from sales of investment property 0.00
Purchase of investment property 0.00
Proceeds from sales of intangible assets 0.00
Purchase of intangible assets 0.00
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 0.00
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets 0.00
Purchase of other long-term assets 0.00
Cash advances and loans made to other parties 0.00
Cash receipts from repayment of advances and loans made to other parties 7,320.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 120.00
Interest received 42,720.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 68,390.00
Net cash flows from (used in) investing activities (8,29,610.00)
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0.00
Payments from changes in ownership interests in subsidiaries 0.00
Proceeds from issuing shares 0.00
Proceeds from issuing other equity instruments 0.00
Payments to acquire or redeem entity's shares 0.00
Payments of other equity instruments 0.00
Proceeds from exercise of stock options 0.00
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 8,26,020.00
Repayments of borrowings 96,790.00
Payments of lease liabilities 2,550.00
Dividends paid 1,10,630.00
Interest paid 35,360.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 19,020.00
Net cash flows from (used in) financing activities 5,99,710.00
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes (18,240.00)
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 21,080.00
Net increase (decrease) in cash and cash equivalents 2,840.00
Cash and cash equivalents cash flow statement at beginning of period 82,680.00
Cash and cash equivalents cash flow statement at end of period 85,520.00





Details of Impact of Audit Qualification

Amount in (Lakhs)

Whether results are audited or unaudited Audited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 Deloitte Haskins & Sells LLP Yes 31-07-2027